Mechanisms of HBV-induced hepatocellular carcinoma

Journal of Hepatology

Volumn 64, Issue 1, 2016, Pages S84-S101

  Levrero, Massimo ^a,b,c   Zucman Rossi, Jessica ^d,e,f  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d INSERM   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f UNIVERSITÉ PARIS 13   (France)

Author keywords

Epigenetics; HBx protein; Hepatitis B virus (HBV); Hepatocellular carcinoma (HCC); miRNAs; preS mutants

Indexed keywords

BETA CATENIN; HEPATITIS B VIRUS X PROTEIN; MUTANT PROTEIN; PROTEIN P53; VIRUS DNA; VIRUS ENVELOPE PROTEIN; WNT PROTEIN; DNA;

CELL PROLIFERATION; CHROMATIN; CHRONIC INFLAMMATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE INSERTION; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; LIVER CELL; LIVER CELL CARCINOMA; LIVER NECROSIS; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; STEM CELL; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; UNFOLDED PROTEIN RESPONSE; VIRUS GENOME; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION; COMPLICATION; GENETICS; HEPATITIS B; LIVER NEOPLASMS; METABOLISM; MUTATION; PATHOLOGY; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; DNA, NEOPLASM; DNA, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MUTATION;

EID: 85010871692     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.02.021     Document Type: Review

References (206)

1. [1] El-Serag, H.B., Rudolph, K.L., Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (2007), 2557–2576.
2. [2] Venook, A.P., Papandreou, C., Furuse, J., de Guevara, L.L., The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 15 (2010), 5–13.
3. [3] Cancer IARC. Globocan. Estimated cancer incidence, mortality and prevalence worldwide in 2012. World Health Organization; 2012. 9, http://globocan iarc fr/Pages/fact_sheets_cancer aspx.
4. [4] McGivern, D.R., Lemon, S.M., Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene, 30, 2011, 1969.
5. [5] Villanueva, A., Llovet, J.M., Targeted therapies for hepatocellular carcinoma. Gastroenterology 140 (2011), 1410–1426.
6. [6] Guerrieri, F., Belloni, L., Pediconi, N., Levrero, M., Molecular mechanisms of HBV-associated hepatocarcinogenesis. Semin Liver Dis 33 (2013), 147–156.
7. [7] Nault, J.C., Zucman-Rossi, J., Genetics of hepatocellular carcinoma: the next generation. J Hepatol 60 (2014), 224–226.
8. [8] Zucman-Rossi, J., Villanueva, A., Nault, J.C., Llovet, J.M., Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149 (2015), 1226–1239.
9. [9] Raimondo, G., Allain, J.P., Brunetto, M.R., et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49 (2008), 652–657.
10. [10] Ahn, S.H., Park, Y.N., Park, J.Y., et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 42 (2005), 188–194.
11. [11] Chen, C.J., Yang, H.I., Su, J., et al. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006), 65–73.
12. [12] Pollicino, T., Squadrito, G., Cerenzia, G., et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 126 (2004), 102–110.
13. [13] Fattovich, G., Stroffolini, T., Zagni, I., Donato, F., Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127 (2004), S35–S50.
14. [14] Sherman, M., Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment. Cleve Clin J Med 76 (2009), S6–S9.
15. [15] Wang, S.H., Yeh, S.H., Lin, W.H., et al. Estrogen receptor a represses transcription of HBV genes via interaction with hepatocyte nuclear factor 4a. Gastroenterology 142 (2012), 989–998.
16. [16] Naugler, W.E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A.M., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317 (2007), 121–124.
17. [17] Donato, F., Tagger, A., Gelatti, U., et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 155 (2002), 323–331.
18. [18] Ming, L., Thorgeirsson, S., Gail, M.H., et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 36 (2002), 1214–1220.
19. [19] Pollicino, T., Vegetti, A., Saitta, C., et al. Hepatitis B virus DNA integration in tumour tissue of a non-cirrhotic HFE-haemochromatosis patient with hepatocellular carcinoma. J Hepatol 58 (2013), 190–193.
20. [20] Seeger, C., Mason, W.S., Molecular biology of hepatitis B virus infection. Virology 479–480 (2015), 672–686.
21. [21] Bock, C.T., Schwinn, S., Locarnini, S., Fyfe, J., Manns, M.P., Trautwein, C., et al. Structural organization of the hepatitis B virus minichromosome. J Mol Biol 307 (2001), 183–196.
22. [22] Levrero, M., Pollicino, T., Petersen, J., Belloni, L., Raimondo, G., Dandri, M., Control of cccDNA function in hepatitis B virus infection. J Hepatol 51 (2009), 581–592.
23. [23] Pollicino, T., Belloni, L., Raffa, G., et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130 (2006), 823–837.
24. [24] Belloni, L., Pollicino, T., De Nicola, F., et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A 106 (2009), 19975–19979.
25. [25] Benhenda, S., Ducroux, A., Rivière, L., Sobhian, B., Ward, M.D., Dion, S., et al. Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription. J Virol 87 (2013), 4360–4371.
26. [26] Cougot, D., Allemand, E., Rivière, L., et al. Inhibition of PP1 phosphatase activity by HBx: a mechanism for the activation of hepatitis B virus transcription. Sci Signal, 5, 2012, 43.
27. [27] EASL clinical practice guidelines: management of CHB. J Hepatol 50 (2009), 227–242.
28. [28] Papatheodoridis, G.V., Lampertico, P., Manolakopoulos, S., Lok, A., Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 53 (2010), 348–356.
29. [29] Tu, T., Mason, W.S., Clouston, A.D., Shackel, N.A., McCaughan, G.W., Yeh, M.M., et al. Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection. J Viral Hepat 22 (2015), 737–753.
30. [30] Di Bisceglie, A.M., Hepatitis B and hepatocellular carcinoma. Hepatology 49 (2009), S56–S60.
31. [31] Chan, H.L., Hui, A.Y., Wong, M.L., Tse, A.M., Hung, L.C., Wong, V.W., et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 53 (2004), 1494–1498.
32. [32] Zoulim, F., Locarnini, S., Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137 (2009), 1593–1608.
33. [33] Kuang, S.Y., Jackson, P.E., Wang, J.B., et al. Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci U S A 101 (2004), 3575–3580.
34. [34] Pollicino, T., Cacciola, I., Saffioti, F., Raimondo, G., Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J Hepatol 61 (2014), 408–417.
35. [35] Liu, S., Zhang, H., Gu, C., Yin, J., He, Y., Xie, J., et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst 101 (2009), 1066–1082.
36. [36] Chen, C.H., Hung, C.H., Lee, C.M., Hu, T.H., Wang, J.H., Wang, J.C., et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 133 (2007), 1466–1474.
37. [37] Bruss, V., Revisiting the cytopathic effect of hepatitis B virus infection. Hepatology 36 (2002), 1327–1329.
38. [38] Chisari, F.V., Filippi, P., McLachlan, A., Milich, D.R., Riggs, M., Lee, S., et al. Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice. J Virol 60 (1986), 880–887.
39. [39] Chisari, F.V., Klopchin, K., Moriyama, T., et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59 (1989), 1145–1156.
40. [40] Wang, H.C., Huang, W., Lai, M.D., Su, I.J., Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci 97 (2006), 683–688.
41. [41] Hsieh, Y.H., Su, I.J., Wang, H.C., Chang, W.W., Lei, H.Y., Lai, M.D., et al. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis 25 (2004), 2023–2032.
42. [42] Hung, J.H., Su, I.J., Lei, H.Y., Wang, H.C., Lin, W.C., Chang, W.T., et al. Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappaB and pp38 mitogen-activated protein kinase. J Biol Chem 279 (2004), 46384–46392.
43. [43] Wang, L.H., Huang, W., Lai, M.D., Su, I.J., Aberrant cyclin A expression and centrosome overduplication induced by hepatitis B virus pre-S2 mutants and its implication in hepatocarcinogenesis. Carcinogenesis 33 (2012), 466–472.
44. [44] Mathai, A.M., Alexander, J., Kuo, F.Y., Torbenson, M., Swanson, P.E., Yeh, M.M., Type II ground-glass hepatocytes as a marker of hepatocellular carcinoma in chronic hepatitis B. Hum Pathol 44 (2013), 1665–1671.
45. [45] Lai, M.W., Yeh, C.T., The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. Antivir Ther 13 (2008), 875–879.
46. [46] Lai, M.W., Huang, S.F., Hsu, C.W., Chang, M.H., Liaw, Y.F., Yeh, C.T., Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. Antivir Ther 14 (2009), 249–261.
47. [47] Lee, S.A., Kim, K., Kim, H., Kim, B.J., Nucleotide change of codon 182 in the surface gene of hepatitis B virus genotype C leading to truncated surface protein is associated with progression of liver diseases. J Hepatol 56 (2012), 63–69.
48. [48] Yeh, C.T., Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy. Antivir Ther 15 (2010), 471–475.
49. [49] Warner, N., Locarnini, S., The antiviral drug selected hepatitis B virus rtA181T/sW172∗ mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 48 (2008), 88–98.
50. [50] Yeh, C.T., Chen, T., Hsu, C.W., Chen, Y.C., Lai, M.W., Liang, K.H., et al. Emergence of the rtA181T/sW172∗ mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer, 21, 2011, 398.
51. [51] Jiang, D.-K., Sun, J., Cao, G., et al. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet 45 (2013), 72–75.
52. [52] Clifford, R.J., Zhang, J., Meerzaman, D.M., et al. Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma. Hepatology 52 (2010), 2034–2043.
53. [53] Chan, K.Y.K., Wong, C.-M., Kwan, J.S.-H., et al. Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection. PLoS One, 6, 2011, e28798.
54. [54] Zhang, H., Zhai, Y., Hu, Z., et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 42 (2010), 767–770.
55. [55] Gu, X., Qi, P., Zhou, F., et al. 149G > A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol 71 (2010), 83–87.
56. [56] Migita, K., Miyazoe, S., Maeda, Y., et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection–association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol 42 (2005), 505–510.
57. [57] Long, X.D., Ma, Y., Qu, D.Y., et al. The polymorphism of XRCC3 codon 241 and AFB1-related hepatocellular carcinoma in Guangxi population, China. Ann Epidemiol 18 (2008), 572–578.
58. [58] Yoon, Y.J., Chang, H.Y., Ahn, S.H., et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 29 (2008), 1192–1196.
59. [59] Yuan, J.-M., Lu, S.C., Van Den Berg, D., et al. Genetic polymorphisms in the methylenetetrahydrofolate reductase and thymidylate synthase genes and risk of hepatocellular carcinoma. Hepatology 46 (2007), 749–758.
60. [60] Wang, B., Huang, G., Wang, D., et al. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol 53 (2010), 508–518.
61. [61] Totoki, Y., Tatsuno, K., Covington, K.R., et al. Transancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 46 (2014), 1267–1273.
62. [62] Schulze, K., Imbeaud, S., Letouze, E., et al. Exome sequencing of hepatocellular carcinoma identifies new mutations signatures and potential therapeutic targets. Nat Genet 47 (2015), 505–511.
63. [63] Guichard, C., Amaddeo, G., Imbeaud, S., et al. Integrated analysis of somatic mutations and focal copynumber changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 44 (2012), 694–698.
64. [64] Huang, J., Deng, Q., Wang, Q., et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 44 (2012), 1117–1121.
65. [65] Cleary, S.P., Jeck, W.R., Zhao, X., et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology 58 (2013), 1693–1702.
66. [66] Ahn, S.-M., Jang, S.J., Shim, J.H., et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 60 (2014), 1972–1982.
67. [67] Kan, Z., Zheng, H., Liu, X., et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res 23 (2013), 1422–1433.
68. [68] Nault, J.C., Mallet, M., Pilati, C., et al. High frequence of telomerase reverse-transcriptase promoter somatic mutations in hepatocellularcarcinoma and preneoplastic lesions. Nat Commun 4 (2013), 1–6.
69. [69] Sung, W.-K., Zheng, H., Li, S., et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 44 (2012), 765–769.
70. [70] Paterlini-Bréchot, P., Saigo, K., Murakami, Y., et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 22 (2003), 3911–3916.
71. [71] Liu, H., Shi, W., Luan, F., Xu, S., Yang, F., Sun, W., et al. Hepatitis B virus X protein upregulates transcriptional activation of human telomerase reverse transcriptase. Virus Genes 40 (2010), 174–182.
72. [72] Luan, F., Liu, H., Gao, L., Liu, J., Sun, Z., Ju, Y., et al. Hepatitis B virus protein preS2 potentially promotes HCC development via its transcriptional activation of hTERT. Gut 58 (2009), 1528–1537.
73. [73] de Coste, La., Romagnolo, B., Billuart, P., et al. Somatic mutations of the beta-catenin gene are frequent inmouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 95 (1998), 8847–8851.
74. [74] Satoh, S., Daigo, Y., Furukawa, Y., et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24 (2000), 245–250.
75. [75] Boyault, S., Rickman, D.S., De Reyniès, A., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45 (2006), 42–52.
76. [76] Amaddeo, G., Cao, Q., Ladeiro, Y., et al. Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas. Gut 64 (2015), 820–829.
77. [77] Bressac, B., Kew, M., Wands, J., et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350 (1991), 429–431.
78. [78] Fujimoto, A., Furuta, M., Shiraishi, Y., et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat Commun 6 (2015), 1–8.
79. [79] Hsu, I.C., Metcalf, R.A., Sun, T., et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350 (1991), 427–428.
80. [80] Fujimoto, A., Totoki, Y., Abe, T., et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44 (2012), 760–764.
81. [81] Sawey, E.T., Chanrion, M., Cai, C., et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 19 (2011), 347–358.
82. [82] Wang, K., Lim, H.Y., Shi, S., et al. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology 58 (2013), 706–717.
83. [83] Sporn, M.B., Liby, K.T., NRF2 and cancer: the good, the bad and the importance of context. Nature 12 (2012), 564–571.
84. [84] DeNicola, G.M., Karreth, F.A., Humpton, T.J., et al. Oncogeneinduced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475 (2011), 106–109.
85. [85] Li, M., Zhao, H., Zhang, X., et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 43 (2011), 828–829.
86. [86] Rudalska, R., Dauch, D., Longerich, T., et al. RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med, 2014, 1–11.
87. [87] Chiang, D.Y., Villanueva, A., Hoshida, Y., et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68 (2008), 6779–6788.
88. [88] Hoshida, Y., Toffanin, S., Lachenmayer, A., et al. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 30 (2010), 35–51.
89. [89] Lee, J.-S., Heo, J., Libbrecht, L., et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12 (2006), 410–416.
90. [90] Yamashita, T., Forgues, M., Wang, W., et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68 (2008), 1451–1461.
91. [91] Villanueva, A., Hoshida, Y., Battiston, C., et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 140 (2011), 1501–1512.
92. [92] Hoshida, Y., Nijman, S.M.B., Kobayashi, M., et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69 (2009), 7385–7392.
93. [93] Villanueva, A., Chiang, D.Y., Newell, P., et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135 (2008), 1972–1983.
94. [94] Kaposi-Novak, P., Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116 (2006), 1582–1595.
95. [95] Coulouarn, C., Factor, V.M., Thorgeirsson, S.S., Transforming growth factor-b gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 47 (2008), 2059–2067.
96. [96] Tovar, V., Alsinet, C., Villanueva, A., et al. IGF activation in a molecular subclass of hepatocellular carcinoma and preclinical efficacy of IGF-1R blockage. J Hepatol 52 (2010), 550–559.
97. [97] Newell, P., Toffanin, S., Villanueva, A., et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 51 (2009), 725–733.
98. [98] Villanueva, A., Alsinet, C., Yanger, K., et al. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology 143 (2012), 1660–1669.
99. [99] Yamashita, T., Wang, X.W., Cancer stem cells in the development of liver cancer. J Clin Invest 123 (2013), 1911–1918.
100. [100] Cairo, S., Armengol, C., De Reyniès, A., et al. Hepatic stemlike phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 14 (2008), 471–484.
101. [101] Woo, H.G., Lee, J.H., Yoon, J.H., et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res 70 (2010), 3034–3041.
102. [102] Sia, D., Hoshida, Y., Villanueva, A., et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144 (2013), 829–840.
103. [103] Villanueva, A., Portela, A., Sayols, S., et al. DNA Methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology 61 (2015), 1945–1956.
104. [104] Toffanin, S., Hoshida, Y., Lachenmayer, A., et al. MicroRNAbased classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 140 (2011), 1618–1628.
105. [105] Lee, J.-S., Chu, I.-S., Heo, J., et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40 (2004), 667–676.
106. [106] Lachenmayer, A., Alsinet, C., Savic, R., et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 18 (2012), 4997–5007.
107. [107] Keng, V.W., Sia, D., Sarver, A.L., et al. Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. Hepatology 57 (2012), 120–130.
108. [108] Imbeaud, S., Ladeiro, Y., Zucman-Rossi, J., Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis 30 (2010), 75–86.
109. [109] Ghidini, M., Braconi, C., Non-coding RNAs in primary liver cancer. Front Med, 2, 2015, 36.
110. [110] Moyo, B., Nicholson, S.A., Arbuthnot, P.B., The role of long non-coding RNAs in hepatitis B virus-related hepatocellular carcinoma. Virus Res 2 (2016), 103–113.
111. [111] Ura, S., Honda, M., Yamashita, T., et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 49 (2009), 1098–1112.
112. [112] Zhang, X., Liu, S., Hu, T., et al. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology 50 (2009), 490–499.
113. [113] Wang, Y., Lu, Y., Toh, S.T., et al. Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J Hepatol 53 (2010), 57–66.
114. [114] Huang, J., Wang, Y., Guo, Y., Sun, S., Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 52 (2010), 60–70.
115. [115] Ji, J., Shi, J., Budhu, A., Yu, Z., Forgues, M., Roessler, S., et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361 (2009), 1437–1447.
116. [116] Yang, X., Zhang, X.F., Lu, X., Jia, H.L., Liang, L., Dong, Q.Z., et al. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology 59 (2014), 1874–1885.
117. [117] Wang, X., Sun, W., Shen, W., Xia, M., Chen, C., Xiang, D., et al. Long Non-coding RNA DILC Represses Self-renewal of Liver Cancer Stem Cells via Inhibiting Autocrine IL-6/STAT[3] Axis. J Hepatol, 2016, 10.1016/j.jhep.01.019.
118. [118] Calvisi, D.F., Ladu, S., Gorden, A., et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 117 (2007), 2713–2722.
119. [119] Zhao, J., Wu, G., Bu, F., et al. Epigenetic silence of ankyrin-repeat-containing, SH3-domain-containing, and proline-rich-region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma. Hepatology 51 (2010), 142–153.
120. [120] Wu, L.M., Yang, Z., Zhou, L., et al. Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One, 5, 2010, e14460.
121. [121] Lachenmayer, A., Toffanin, S., Cabellos, L., et al. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol 56 (2012), 1343–1350.
122. [122] Simon, J.A., Lange, C.A., Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647 (2008), 21–29.
123. [123] Sasaki, M., Ikeda, H., Itatsu, K., et al. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest, 88, 2008, 873.
124. [124] Cai, M.Y., Tong, Z.T., Zheng, F., et al. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut, 60, 2011, 967.
125. [125] Sciarra, A., Di Tommaso, L., Nakano, M., Destro, A., Torzilli, G., Donadon, M., et al. Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications. J Hepatol 64 (2016), 87–93.
126. [126] Chen, Y., Lin, M.C., Yao, H., et al. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through downregulation of stathmin. Hepatology, 46, 2007, 200.
127. [127] Yang, F., Zhang, L., Huo, X.S., et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology, 54, 2011, 1679.
128. [128] Cheng, A.S., Lau, S.S., Chen, Y., et al. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin dependent hepato-carcinogenesis. Cancer Res, 71, 2011, 4028.
129. [129] Bouchard, M.J., Navas-Martin, S., Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett, 305, 2011.
130. [130] Garcia, M., de The, H., Tiollais, P., Samarut, J., Dejean, A., A hepatitis B virus pre-S-retinoic acid receptor beta chimera transforms erythrocytic progenitor cells in vitro. Proc Natl Acad Sci U S A 90 (1993), 89–93.
131. [131] Wang, J., Zindy, F., Chenivesse, X., Lamas, E., Henglein, B., et al. Modification of cyclin A expression by hepatitis B virus DNA integration in a hepatocellular carcinoma. Oncogene 7 (1992), 1653–1656.
132. [132] Ferber, M.J., Montoya, D.P., Yu, C., et al. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 22 (2003), 3813–3820.
133. [133] Gozuacik, I., Murakami, Y., Saigo, K., et al. Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging. Oncogene 20 (2001), 6233–6240.
134. [134] Murakami, Y., Saigo, K., Takashima, H., et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 54 (2005), 1162–1168.
135. [135] Saitta, C., Tripodi, G., Barbera, A., Bertuccio, A., Smedile, A., Ciancio, A., et al. Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma. Liver Int 35 (2015), 2311–2317.
136. [136] Ding, D., Lou, X., Hua, D., Yu, W., Li, L., Wang, J., et al. Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach. PLoS Genet, 8, 2012, e1003065.
137. [137] Lau, C.C., Sun, T., Ching, A.K., et al. Viral-human chimeric transcript predisposes risk to liver cancer development and progression. Cancer Cell 25 (2014), 335–349.
138. [138] Liang, H.W., Wang, N., Wang, Y., Wang, F., Fu, Z., Yan, X., et al. Hepatitis B virus-human chimeric transcript HBx-LINE1 promotes hepatic injury via sequestering cellular microRNA-122. J Hepatol 64 (2016), 278–291.
139. [139] Cao, Q., Imbeaud, S., Datta, S., Zucman-Rossi, J., Authors’ response: virus-host interactions in HBV-related hepatocellular carcinoma: more to be revealed?. Gut 64 (2015), 853–854.
140. [140] Chen, Y., Shen, A., Rider, P.J., Yu, Y., Wu, K., Mu, Y., et al. A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB J 25 (2011), 4511–4521.
141. [141] Wang, S., Qiu, L., Yan, X., Jin, W., Wang, Y., Chen, L., et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1) -modulated P53 activity. Hepatology 55 (2012), 730–741.
142. [142] Tsai, W.C., Hsu, S.D., Hsu, C.S., Lai, T.C., Chen, S.J., Shen, R., et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 122 (2012), 2884–2897.
143. [143] Hsu, S.H., Wang, B., Kota, J., Yu, J., Costinean, S., Kutay, H., et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 122 (2012), 2871–2883.
144. [144] Kawai, H., Suda, T., Aoyagi, Y., et al. Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: comparison of loss of heterozygosity and replication error. Hepatology 31 (2000), 1246–1250.
145. [145] Aoki, H., Kajino, K., Arakawa, Y., Hino, O., Molecular cloning of a rat chromosome putative recombinogenic sequence homologous to the hepatitis B virus encapsidation signal. Proc Natl Acad Sci U S A 93 (1996), 7300–7304.
146. [146] Forgues, M., Difilippantonio, M.J., Linke, S.P., et al. Involvement of Crm1 in hepatitis B virus X protein-induced aberrant centriole replication and abnormal mitotic spindles. Mol Cell Biol 23 (2003), 5282–5292.
147. [147] Terradillos, O., Billet, O., Renard, C.A., et al. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 14 (1997), 395–404.
148. [148] Lucifora, J., Arzberger, S., Durantel, D., et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 55 (2011), 996–1003.
149. [149] Ducroux, A., Benhenda, S., Rivière, L., et al. The Tudor domain protein Spindlin1 is involved in intrinsic antiviral defense against incoming hepatitis B Virus and herpes simplex virus type 1. PLoS Pathog, 10, 2014, e1004343.
150. [150] Rivière, L., Gerossier, L., Ducroux, A., Dion, S., Deng, Q., Michel, M.L., et al. HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase. J Hepatol 63 (2015), 1093–1102.
151. [151] Wei, X., Xiang, T., Ren, G., Tan, C., et al. MiR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell Signal 25 (2013), 439–446.
152. [152] Guerrieri, F., Belloni, L., D'Andrea, D., Genome-wide identification of direct HBx targets that control HBV replication. Gastroenterology, 2015.
153. [153] Huang, H.C., Chen, C.C., Chang, W.C., et al. Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis. J Virol 86 (2012), 9443–9453.
154. [154] Macovei, A., Petrareanu, C., Lazar, C., et al. Regulation of hepatitis B virus infection by Rab5, Rab7, and the endolysosomal compartment. J Virol 87 (2013), 6415–6427.
155. [155] Sir, D., Tian, Y., Chen, W.L., Ann, D.K., et al. The early autophagic pathway is activated by hepatitis B virus and required for viral DNA replication. Proc Natl Acad Sci U S A 107 (2010), 4383–4388.
156. [156] Hodgson, A.J., Hyser, J.M., Keasler, V.V., et al. Hepatitis B virus regulatory HBx protein binding to DDB1 is required but is not sufficient for maximal HBV replication. Virology 426 (2012), 73–82.
157. [157] Yang, B., Bouchard, M.J., The hepatitis B virus X protein elevates cytosolic calcium signals by modulating mitochondrial calcium uptake. J Virol 86 (2012), 313–327.
158. [158] Cougot, D., Wu, Y., Cairo, S., et al. The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription. J Biol Chem 282 (2007), 4277–4287.
159. [159] Studach, L.L., Menne, S., Cairo, S., et al. Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein. Hepatology 56 (2012), 1240–1251.
160. [160] Zhang, H., Diab, A., Fan, H., et al. PLK1 and HOTAIR accelerate proteasomal degradation of SUZ12 and ZNF198 during hepatitis B virus-induced liver carcinogenesis. Cancer Res, 2015.
161. [161] Fan, H., Zhang, H., Pascuzzi, P.E., Andrisani, O., Hepatitis B virus X protein induces EpCAM expression via active DNA demethylation directed by RelA in complex with EZH2 and TET2. Oncogene, 2015.
162. [162] Park, I.Y., Sohn, B.H., Yu, E., et al. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 132 (2007), 1476–1494.
163. [163] Zheng, D.L., Zhang, L., Cheng, N., et al. Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J Hepatol 50 (2009), 377–387.
164. [164] Plentz, R.R., Park, Y.N., Lechel, A., et al. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology 45 (2007), 968–976.
165. [165] Wiemann, S.U., Satyanarayana, A., Tsahuridu, M., et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 16 (2002), 935–942.
166. [166] Kang, T.W., Yevsa, T., Woller, N., et al. Senescence surveillance of premalignant hepatocytes limits liver cancer development. Nature 479 (2011), 547–551.
167. [167] Kojima, H., Yokosuka, O., Imazeki, F., et al. Telomerase activity and telomere length in hepatocellular carcinoma and chronic liver disease. Gastroenterology 112 (1997), 493–500.
168. [168] Nault, J.C., Calderaro, J., Di Tommaso, L., et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 60 (2014), 1983–1992.
169. [169] Ozturk, M., Arslan-Ergul, A., Bagislar, S., et al. Senescence and Immortality in Hepatocellular Carcinoma. Cancer Lett 286 (2009), 103–113.
170. [170] Wang, X.W., Forrester, K., Yeh, H., Feitelson, M.A., Gu, J.R., Harris, C.C., Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A 91 (1994), 2230–2234.
171. [171] Park, S.H., Jung, J.K., Lim, J.S., Tiwari, I., Jang, K.L., Hepatitis B virus X protein overcomes all-trans retinoic acid-induced cellular senescence by down-regulating levels of p16 and p21 via DNA methylation. J Gen Virol 92 (2011), 1309–1317.
172. [172] Li, J., Liu, Y., Wang, Z., et al. Subversion of cellular autophagy machinery by hepatitis B virus for viral envelopment. J Virol 85 (2011), 6319–6333.
173. [173] Clippinger, A.J., Bouchard, M.J., Hepatitis B virus HBx protein localizes to mitochondria in primary rat hepatocytes and modulates mitochondrial membrane potential. J Virol 82 (2008), 6798–6811.
174. [174] Cho, H.K., Cheong, K.J., Kim, H.Y., Cheong, J., Endoplasmic reticulum stress induced by hepatitis B virus X protein enhances cyclo-oxygenase 2 expression via activating transcription factor 4. Biochem J 435 (2011), 431–439.
175. [175] Pan, J., Lian, Z., Wallett, S., Feitelson, M.A., The hepatitis B x antigen effector, URG7, blocks tumour necrosis factor α-mediated apoptosis by activation of phosphoinositol 3-kinase and β-catenin. J Gen Virol 88 (2007), 3275–3285.
176. [176] Pang, R., Lee, T.K., Poon, R.T., et al. Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis. Gastroenterology 132 (2007), 1088–1103.
177. [177] Yoo, Y.G., Oh, S.H., Park, E.S., et al. Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1α through activation of mitogen activated protein kinase pathway. J Biol Chem 278 (2003), 39076–39084.
178. [178] Sanz-Camern, P., Martín-Vílchez, S., Lara-Pezzi, E., et al. Hepatitis B virus core proteins shift TGF-β responses from tumor suppression to promotes angiopoietin-2 expression in liver tissue. Role of HBV X protein. Am J Pathol 169 (2006), 1215–1222.
179. [179] Battaglia, S., Benzoubir, N., Nobilet, S., et al. Liver cancer-derived hepatitis C virus epithelial-mesenchymal transition. PLoS One, 4, 2009, e4355.
180. [180] Benzoubir, N., Lejamtel, C., Battaglia, S., et al. HCV core-mediated activation of latent TGF-β via thrombospondin drives the cross-talk between hepatocytes and stromal environment. J Hepatol 59 (2013), 1160–1168.
181. [181] Yoo, Y.D., Ueda, H., Park, K., et al. Regulation of transforming growth factor-β 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J Clin Invest 97 (1996), 388–395.
182. [182] Lee, D.K., Park, S.H., Yi, Y., et al. The hepatitis B virus encoded oncoprotein pX amplifies TGF-β family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis. Genes Dev 15 (2001), 455–466.
183. [183] Arzumanyan, A., Friedman, T., Kotei, E., Ng, I.O., Lian, Z., Feitelson, M.A., Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer. Oncogene 31 (2012), 563–572.
184. [184] Arzumanyan, A., Friedman, T., Ng, I.O., Clayton, M.M., Lian, Z., Feitelson, M.A., Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells?. Cancer Res 71 (2011), 3701–3708.
185. [185] Yamashita, T., Budh, A., Forgues, M., Wang, X.W., Activation of hepatic stem cell marker EpCAM by Wnt-β-catenin signaling in hepatocellular carcinoma. Cancer Res 67 (2007), 10831–10839.
186. [186] Yamashita, T., Ji, J., Budhu, A., et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136 (2009), 1012–1024.
187. [187] Ji, J., Yamashita, T., Budhu, A., et al. Identification of microRNA-181 by genome wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 50 (2009), 472–480.
188. [188] Sell, S., Leffert, H.L., Liver cancer stem cells. J Clin Oncol 26 (2008), 2800–2805.
189. [189] Iavarone, M., Trabut, J.B., Delpuech, O., et al. Characterisation of hepatitis B virus X protein mutants in tumour and non-tumour liver cells using laser capture microdissection. J Hepatol 39 (2003), 253–261.
190. [190] Kim, C.M., Koike, K., Saito, I., et al. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351 (1991), 317–320.
191. [191] Ma, N.F., Lau, S.H., Hu, L., et al. COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis. Clin Cancer Res 14 (2008), 5061–5068.
192. [192] Belloni L, li L, Palumbo GA et al. HAPs hepatitis B virus (HBV) capsid inhibitors block core protein interaction with the viral minichromosome and host cell genes and affect cccDNA transcription and stability. AASLD 2013 Hepatology 58, S1, 138 10.
193. [193] Gruffaz M, Testoni B, Durantel D et al. Hepatitis B core (HBc) protein is a key and very early negative regulator of the interferon response. AASLD 2013 Hepatology, 58, S1, 136 56.
194. [194] Guo, Y., Kang, W., Lei, X., et al. Hepatitis B viral core protein disrupts human host gene expression by binding to promoter regions. BMC Genomics, 13, 2012, 563.
195. [195] Wang, H.C., Chang, W.T., Chang, W.W., Wu, H.C., Huang, W., Lei, H.Y., et al. Hepatitis B virus pre-S2 mutant upregulates cyclin A expression and induces nodular proliferation of hepatocytes. Hepatology 41 (2005), 761–770.
196. [196] Yang, J.C., Teng, C.F., Wu, H.C., Tsai, H.W., Chuang, H.C., Tsai, T.F., et al. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology 49 (2009), 1962–1971.
197. [197] Hsieh, Y.H., Su, I.J., Wang, H.C., Tsai, J.H., Huang, Y.J., Chang, W.W., et al. Hepatitis B virus pre-S2 mutant surface antigen induces degradation of cyclin-dependent kinase inhibitor p27Kip1 through c-Jun activation domain-binding protein 1. Mol Cancer Res 5 (2007), 1063–1072.
198. [198] Caselmann, W.H., Meyer, M., Kekule, A.S., Lauer, U., Hofschneider, P.H., Koshy, R., A trans-activator function is generated by integration of hepatitis B virus preS/S sequences in human hepatocellular carcinoma DNA. Proc Natl Acad Sci U S A 87 (1990), 2970–2974.
199. [199] Hildt, E., Saher, G., Bruss, V., Hofschneider, P.H., The hepatitis B virus large surface protein (LHBs) is a transcriptional activator. Virology 225 (1996), 235–239.
200. [200] Kekule, A.S., Lauer, U., Meyer, M., Caselmann, W.H., Hofschneider, P.H., Koshy, R., The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature 343 (1990), 3335–3344.
201. [201] Schluter, V., Meyer, M., Hofschneider, P.H., Koshy, R., Caselmann, W.H., Integrated hepatitis B virus X and 30 truncated preS/S sequences derived from human hepatomas encode functionally active transactivators. Oncogene 9 (1994), 3335–3344.
202. [202] Zhong, S., Chan, J.Y., Yeo, W., Tam, J.S., Johnson, P.J., Hepatitis B envelope protein mutants in human hepatocellular carcinoma tissues. J Viral Hepat 6 (1999), 195–202.
203. [203] Hildt, E., Munz, B., Saher, G., et al. The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice. EMBO J 21 (2002), 525–535.
204. [204] Tomasetti, C., Vogelstein, B., Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347 (2015), 78–81.
205. [205] He, G., Dhar, D., Nakagawa, H., et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 155 (2013), 384–396.
206. [206] Font-Burgada, J., Shalapour, S., Ramaswamy, S., et al. Cell. Hybrid Periportal Hepatocytes Regenerate the Injured Liver without Giving Rise to Cancer. Cell 162 (2015), 766–779.